2026-07-14T18:23:12.848Z / 路透社
2026年2月5日，美国总统唐纳德·特朗普在华盛顿特区白宫园区南庭礼堂出席特朗普Rx药品折扣网站揭幕活动。路透社/阿尔·德拉戈 购买授权链接，将在新标签页打开
- 摘要
- 公司动态
- 和解协议将把 TrumpRx 采购额计入部分保险计划的免赔额
- FTC 表示，CVS 必须为客户提供退出返利支付模式的选项
- CVS 表示将把胰岛素自付费用上限设定为每月25美元
纽约7月14日路透电 – FTC 发言人周二表示，CVS健康公司旗下的Caremark已与美国联邦贸易委员会达成最终和解协议，同意限制使用所谓返利的售后折扣，并将消费者通过TrumpRx平台的药品采购额计入其保险免赔额。
与今年早些时候信诺与 FTC 达成的和解类似，此次协议将限制批评人士所称的推高药品价格的行为。协议还要求，一旦相关监管规定出台以推动TrumpRx项目落地，CVS旗下的药房福利管理部门Caremark需将患者通过TrumpRx药品网站支付的费用，纳入其部分健康保险计划要求的免赔额计算范围。
路透每日简报通讯为您提供开启一天所需的全部新闻。点击此处订阅。
FTC主席安德鲁·弗格森在一份声明中表示，此次和解预计将为药品价格带来数十亿美元的节省。
“在特朗普总统任期内的FTC不会容忍推高美国消费者药品价格的反竞争行为，”弗格森说道。
美国总统唐纳德·特朗普于今年2月推出了TrumpRx.gov网站，为消费者提供数百种仿制药和品牌药折扣，特别聚焦于帮助消费者以低价购买礼来公司（LLY.N）和诺和诺德公司（NOVOb.CO）的热门减肥药物。
健康保险计划的免赔额是指会员在获得保险覆盖前必须自行承担的最低消费金额。TrumpRx.gov将现金支付客户引导至制药商网站购买折扣药品，但该平台一直游离于保险体系之外，限制了其对部分美国消费者的价值。
FTC发言人表示，CVS还必须为客户提供退出返利支付模式的选项。这类返利由制药商支付给药房福利管理机构，在药品配发给患者后，返利可能会也可能不会转交给保险计划发起人或消费者。
小型药店还将获得选择按实际配药成本加服务费获得报销的权利，以回应有关药房福利管理机构未全额报销独立本地药店费用的投诉。
“今日的协议推进并巩固了我们已实施的改革，确保全国家庭和患者都能负担得起药品费用，”Caremark总裁埃德·德文尼说道。
CVS一位发言人表示，取消返利的具体决定将取决于客户情况以及各雇主如何规划自身的药房福利。但该公司表示，其目标是鼓励客户将折扣转嫁给个人会员。
FTC于2024年发起的最初诉讼称，Caremark、信诺旗下的Express Scripts以及联合健康旗下的OptumRx迫使患者为胰岛素支付更高价格。
CVS于今年3月与监管机构达成了拟议和解协议，FTC表示该协议与Express Scripts达成的和解类似。
监管机构表示，返利模式会激励企业提高药品标价，最终引导消费者购买价格更高的药品。
药房福利管理机构代表雇主等保险计划发起人，与制药商协商药品价格。
CVS表示，该公司还将加强对药品价格和收到的会员付款的报告，转向基于服务费的薪酬结构，并将胰岛素自付费用上限设定为每月25美元。
本报纽约记者阿米娜·尼亚斯和约迪·戈多伊报道；编辑：卡罗琳·休默和奥罗拉·埃利斯
我们的标准：汤森路透信托原则。
CVS settles with FTC, agrees to count TrumpRx drug purchases towards insurance
2026-07-14T18:23:12.848Z / Reuters
U.S. President Donald Trump arrives to an event to unveil the TrumpRx drug discount site, in the South Court Auditorium on the White House campus, in Washington, D.C., U.S., February 5, 2026. REUTERS/Al Drago Purchase Licensing Rights, opens new tab
- Summary
- Companies
- Settlement would count TrumpRx purchases toward some plan deductibles
- CVS must offer clients an option to opt out of rebate payment models, the FTC said
- CVS said it would cap insulin out-of-pocket costs at $25 per month
NEW YORK, July 14 (Reuters) – CVS Health’s
(CVS.N)
Caremark has finalized a settlement with the U.S. Federal Trade Commission in which it agreed to curb use of after-market discounts known as rebates and count consumers’ TrumpRx purchases toward their deductibles, an FTC spokesperson said on Tuesday.
Similar to Cigna’s settlement with the FTC earlier this year, the deal would curb practices critics say contribute to high drug costs. It would also require CVS’ Caremark pharmacy benefit manager to include a patient’s payments through the TrumpRx drug website toward the deductibles some of its health plans require, once regulations are in place to facilitate the TrumpRx program.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
The settlement is expected to bring billions of dollars in savings on drug prices, FTC Chairman Andrew Ferguson said in a statement.
“The FTC under President Trump won’t stand for anticompetitive behavior that drives up prices for American consumers,” Ferguson said.
U.S. President Donald Trump launched TrumpRx.gov, a website offering hundreds of generic and branded drugs at a discount, in February, with a particular focus on connecting consumers with low prices for highly popular weight-loss drugs from Eli Lilly
(LLY.N)
and Novo Nordisk
(NOVOb.CO)
.
Health plan deductibles are the minimum spend members must reach before leveraging their coverage. TrumpRx.gov sends cash-pay customers to drugmaker websites for discounted drugs, but has operated outside of insurance, limiting its value for some American consumers.
CVS must also provide an option to clients that allows them to opt out of rebate payment models, a spokesperson for the FTC said. These rebates are paid by drugmakers to the pharmacy benefit manager and may or may not be passed on to the plan sponsor or consumer after a certain drug is dispensed.
Small pharmacies would also be given the option to be reimbursed for the actual cost of drugs they dispense plus a fee, in a bid to address complaints that pharmacy benefit managers do not fully reimburse independent local pharmacies.
“Today’s agreement advances and reinforces the changes we have already put in place and ensures affordability for families and patients across the country,” said Ed DeVaney, a president at Caremark.
The decision to eliminate rebates will vary based on the client and how individual employers choose to structure their own pharmacy benefit, a spokesperson for CVS said. But the company aims to encourage its clients to pass through discounts to individual members, CVS said in a release on Tuesday.
The FTC’s original lawsuit, launched in 2024, said Caremark, Cigna’s
(CI.N)
Express Scripts, and UnitedHealth’s OptumRx
(UNH.N)
forced patients to pay higher prices for insulin.
CVS reached a proposed settlement with the regulator in March, and the FTC said the deal was similar to one with Express Scripts.
Regulators have said the rebate model incentivizes companies to raise list prices and ultimately steers customers to pricier drugs.
Pharmacy benefit managers negotiate the price of drugs with manufacturers, on behalf of plan sponsors, such as employers.
CVS will also enhance its reporting on the price of drugs and member payments it receives, shift to a fee-based compensation structure, and cap out-of-pocket cost of insulin at $25 per month, the company said.
Reporting by Amina Niasse and Jody Godoy in New York; editing by Caroline Humer and Aurora Ellis
Our Standards: The Thomson Reuters Trust Principles.
发表回复